USPTO serial 86879881
GLOBOVAX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- HACK, ANDREA R
- Law office
- TMEG LAW OFFICE 108 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with GLOBOVAX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jonathan O. Owens
JONATHAN O. OWENS HAVERSTOCK & OWENS LLP162 NORTH WOLFE ROADSUNNYVALE, CA 94086UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | adjuvants for medical purposes; amino acids for medical purposes; amino acids for veterinary purposes; soap-bark tree, quillaja, quillais and Quillaja saponaria Molina barks for pharmaceutical purposes; biological preparations for medical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; biological preparations for veterinary purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; chemical reagents for medical or veterinary purposes; chemical preparations for medical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; chemical preparations for pharmaceutical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; chemical preparations for veterinary purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; chemico-pharmaceutical preparations for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; drugs for medical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; glucose for medical purposes; milk sugar for pharmaceutical purposes; lactose for pharmaceutical purposes; medicinal roots; medicinal herbs; medicinal oils; medicinal infusions for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; medicines for human purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; medicines for veterinary purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; pharmaceutical preparations for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; phosphates for pharmaceutical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; potassium salts for medical purposes; reagent paper for medical or veterinary purposes; mineral salts for medical purposes; sodium salts for medical purposes; sugar for medical purposes; vaccines; veterinary preparations for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; yeast for pharmaceutical purposes; acetates for pharmaceutical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; acids for pharmaceutical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; alginates for pharmaceutical purposes; blood for medical purposes; blood plasma; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; diastase for medical purposes; enzyme preparations for medical purposes; enzymes for medical purposes; ferments for pharmaceutical purposes; medicated pastilles for pharmaceutical purposes; medicated lozenges for pharmaceutical purposes; flour for pharmaceutical purposes; meal for pharmaceutical purposes; hormones for medical purposes; milk ferments for pharmaceutical purposes; cultures of microorganisms for medical and veterinary use; preparations of microorganisms for medical and veterinary use, namely, nutritive substances for microorganisms for medical and veterinary use; serotherapeutic medicines for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; medicated serums for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; stem cells for medical purposes; anti-cancer preparations; adjuvants for use with vaccines; biological preparations for the treatment of cancer. drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; ferments for medical or veterinary use; human vaccine preparations; medicinal preparations for the treatment of infectious diseases and for use in oncology; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical products for the prevention and treatment of cancer; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; reagents for medical use; vaccine adjuvants; vaccine preparations; vaccine stabilizers | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 12, 2018 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jun 12, 2018 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Feb 20, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 14, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 14, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 14, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 14, 2017 | OTHE | CASE RETURNED TO EXAMINATION | — |
| Nov 14, 2017 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Nov 2, 2017 | ATRQ | ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED | — |
| Nov 2, 2017 | PCBG | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | — |
| Oct 31, 2017 | APET | ASSIGNED TO PETITION STAFF | — |
| Oct 31, 2017 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 27, 2017 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Oct 27, 2017 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Oct 27, 2017 | EXT2 | SOU EXTENSION 2 FILED | — |
| Oct 27, 2017 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 9, 2017 | TPAD | TEAS PETITION TO AMEND BASIS RECEIVED | — |
| Mar 14, 2017 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 10, 2017 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 10, 2017 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 10, 2017 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 1, 2016 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 6, 2016 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 6, 2016 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 17, 2016 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 3, 2016 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Aug 2, 2016 | ALIE | ASSIGNED TO LIE | — |
| Jul 21, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 15, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 14, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 14, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 8, 2016 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 8, 2016 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 8, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 8, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 26, 2016 | MPMK | NOTICE OF PSEUDO MARK E-MAILED | — |
| Jan 25, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 22, 2016 | NWAP | NEW APPLICATION ENTERED | — |